Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H14O3 |
| Molecular Weight | 230.2597 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]([H])(c1ccc2cc(ccc2c1)OC)C(=O)O
InChI
InChIKey=CMWTZPSULFXXJA-VIFPVBQESA-N
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
| Molecular Formula | C14H14O3 |
| Molecular Weight | 230.2597 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdfCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68009288
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68009288
Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf
Curator's Comment:: Naproxen is a potent inhibitor of prostaglandin synthesis in vitro. Naproxen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL221 |
0.11 µM [IC50] | ||
Target ID: CHEMBL230 |
0.19 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NAPROSYN Approved UseNAPROSYN is indicated:
For the relief of the signs and symptoms of rheumatoid arthritis.
For the relief of the signs and symptoms of osteoarthritis.
For the relief of the signs and symptoms of ankylosing spondylitis.
For the relief of the signs and symptoms of juvenile arthritis.
NAPROSYN is also indicated:
For relief of the signs and symptoms of tendonitis.
For relief of the signs and symptoms of bursitis.
For relief of the signs and symptoms of acute gout.
For the management of pain.
For the management of primary dysmenorrhea. Launch Date1.95350397E11 |
|||
| Primary | NAPROSYN Approved UseNAPROSYN is indicated:
For the relief of the signs and symptoms of rheumatoid arthritis.
For the relief of the signs and symptoms of osteoarthritis.
For the relief of the signs and symptoms of ankylosing spondylitis.
For the relief of the signs and symptoms of juvenile arthritis.
NAPROSYN is also indicated:
For relief of the signs and symptoms of tendonitis.
For relief of the signs and symptoms of bursitis.
For relief of the signs and symptoms of acute gout.
For the management of pain.
For the management of primary dysmenorrhea. Launch Date1.95350397E11 |
|||
| Primary | NAPROSYN Approved UseNAPROSYN is indicated:
For the relief of the signs and symptoms of rheumatoid arthritis.
For the relief of the signs and symptoms of osteoarthritis.
For the relief of the signs and symptoms of ankylosing spondylitis.
For the relief of the signs and symptoms of juvenile arthritis.
NAPROSYN is also indicated:
For relief of the signs and symptoms of tendonitis.
For relief of the signs and symptoms of bursitis.
For relief of the signs and symptoms of acute gout.
For the management of pain.
For the management of primary dysmenorrhea. Launch Date1.95350397E11 |
|||
| Primary | NAPROSYN Approved UseNAPROSYN is indicated:
For the relief of the signs and symptoms of rheumatoid arthritis.
For the relief of the signs and symptoms of osteoarthritis.
For the relief of the signs and symptoms of ankylosing spondylitis.
For the relief of the signs and symptoms of juvenile arthritis.
NAPROSYN is also indicated:
For relief of the signs and symptoms of tendonitis.
For relief of the signs and symptoms of bursitis.
For relief of the signs and symptoms of acute gout.
For the management of pain.
For the management of primary dysmenorrhea. Launch Date1.95350397E11 |
|||
| Primary | NAPROSYN Approved UseNAPROSYN is indicated:
For the relief of the signs and symptoms of rheumatoid arthritis.
For the relief of the signs and symptoms of osteoarthritis.
For the relief of the signs and symptoms of ankylosing spondylitis.
For the relief of the signs and symptoms of juvenile arthritis.
NAPROSYN is also indicated:
For relief of the signs and symptoms of tendonitis.
For relief of the signs and symptoms of bursitis.
For relief of the signs and symptoms of acute gout.
For the management of pain.
For the management of primary dysmenorrhea. Launch Date1.95350397E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
95 μg/L |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NAPROXEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
94 μg/mL |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NAPROXEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1446 μg × h/mL |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NAPROXEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1448 μg × h/mL |
1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NAPROXEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15 h |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NAPROXEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NAPROXEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: Page: 1102/129 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: 1102/129 |
Disc. AE: Abdominal pain, Nausea... AEs leading to discontinuation/dose reduction: Abdominal pain Sources: Page: 1102/129Nausea Dizziness Seizures Metabolic acidosis (severe) |
4 g single, oral Highest studied dose Dose: 4 g Route: oral Route: single Dose: 4 g Sources: Page: p.272 |
healthy, 20 n = 4 Health Status: healthy Age Group: 20 Sex: M Population Size: 4 Sources: Page: p.272 |
|
70.4 g single, oral Overdose Dose: 70.4 g Route: oral Route: single Dose: 70.4 g Co-administed with:: alcohol, p.o Sources: Page: p.103 |
healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: M Population Size: 1 Sources: Page: p.103 |
Disc. AE: Sinus tachycardia, Drowsiness... AEs leading to discontinuation/dose reduction: Sinus tachycardia Sources: Page: p.103Drowsiness Metabolic acidosis Seizures |
26 g single, oral Overdose Dose: 26 g Route: oral Route: single Dose: 26 g Sources: Page: p.458 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Depressive syndrome|Anxiety Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.458 |
Disc. AE: Thrombopenia... AEs leading to discontinuation/dose reduction: Thrombopenia Sources: Page: p.458 |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (grade 3-5) Sources: Page: p.1Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (grade 3-5) Gastrointestinal bleeding (grade 3-5) Gastrointestinal ulcer (grade 3-5) Perforation stomach (grade 3-5) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Abdominal pain | Disc. AE | 12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: Page: 1102/129 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: 1102/129 |
| Dizziness | Disc. AE | 12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: Page: 1102/129 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: 1102/129 |
| Nausea | Disc. AE | 12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: Page: 1102/129 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: 1102/129 |
| Seizures | Disc. AE | 12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: Page: 1102/129 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: 1102/129 |
| Metabolic acidosis | severe Disc. AE |
12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: Page: 1102/129 |
healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: Page: 1102/129 |
| Drowsiness | Disc. AE | 70.4 g single, oral Overdose Dose: 70.4 g Route: oral Route: single Dose: 70.4 g Co-administed with:: alcohol, p.o Sources: Page: p.103 |
healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: M Population Size: 1 Sources: Page: p.103 |
| Metabolic acidosis | Disc. AE | 70.4 g single, oral Overdose Dose: 70.4 g Route: oral Route: single Dose: 70.4 g Co-administed with:: alcohol, p.o Sources: Page: p.103 |
healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: M Population Size: 1 Sources: Page: p.103 |
| Seizures | Disc. AE | 70.4 g single, oral Overdose Dose: 70.4 g Route: oral Route: single Dose: 70.4 g Co-administed with:: alcohol, p.o Sources: Page: p.103 |
healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: M Population Size: 1 Sources: Page: p.103 |
| Sinus tachycardia | Disc. AE | 70.4 g single, oral Overdose Dose: 70.4 g Route: oral Route: single Dose: 70.4 g Co-administed with:: alcohol, p.o Sources: Page: p.103 |
healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: M Population Size: 1 Sources: Page: p.103 |
| Thrombopenia | Disc. AE | 26 g single, oral Overdose Dose: 26 g Route: oral Route: single Dose: 26 g Sources: Page: p.458 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Depressive syndrome|Anxiety Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.458 |
| Cardiac thrombosis | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
| Gastrointestinal bleeding | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
| Gastrointestinal disorder NOS | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
| Gastrointestinal ulcer | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
| Myocardial infarction | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
| Perforation stomach | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
| Stroke | grade 3-5 Disc. AE |
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis Sources: Page: p.1 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [IC50 4.67 uM] | ||||
| yes [IC50 486 uM] | ||||
| yes [IC50 5.67 uM] | ||||
| yes [IC50 85.4 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | ||||
| minor | ||||
| minor | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. | 2000 Sep |
|
| Synthesis of some new 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones and their anti-inflammatory activities. | 2001 |
|
| [Two complex suicidal poisonings with drugs and their medicolegal aspects]. | 2001 |
|
| Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. | 2001 |
|
| Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts. | 2001 |
|
| Nimesulide, a balanced drug for the treatment of osteoarthritis. | 2001 |
|
| Naproxen particle design using porous starch. | 2001 Apr |
|
| Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets. | 2001 Apr |
|
| Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. | 2001 Apr |
|
| Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. | 2001 Apr |
|
| Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. | 2001 Apr |
|
| Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. | 2001 Apr |
|
| Uniformly sized molecularly imprinted polymer for (S)-naproxen retention and molecular recognition properties in aqueous mobile phase. | 2001 Apr 13 |
|
| [Acupuncture contra antiphlogistics in acute lumbago]. | 2001 Apr 20 |
|
| I'm taking over-the-counter ibuprofen every day for neck pain. Recently, my doctor gave me a prescription for naproxen for my arthritis. Should I be concerned about taking these two together? | 2001 Aug |
|
| Localization of cyclooxygenase isozymes in cardiovascular tissues of dogs treated with naproxen. | 2001 Aug 10 |
|
| [Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study in the French Pharmacovigilance Database]. | 2001 Jan-Feb |
|
| A possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes. | 2001 Jul |
|
| New issues about nitric oxide and its effects on the gastrointestinal tract. | 2001 Jul |
|
| Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. | 2001 Jul |
|
| Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. | 2001 Jul |
|
| Addition of hydrogen bond donating excipients to oil solution: effect on in vitro drug release rate and viscosity. | 2001 Jul |
|
| Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. | 2001 Jul |
|
| Determination of ibuprofen and naproxen in tablets. | 2001 Jul |
|
| In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium. | 2001 Jul-Aug |
|
| In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes. | 2001 Jun |
|
| Determination of naproxen in pharmaceutical preparations by room-temperature phosphorescence. A comparative study of several organized media. | 2001 Jun |
|
| By the way, doctor. Which drugs cause problems in the sun? | 2001 Jun |
|
| [Treatment of pain due to unwanted lactation with a homeopathic preparation given in the immediate post-partum period]. | 2001 Jun |
|
| Fixed drug eruption due to naproxen; lack of cross-reactivity with other propionic acid derivatives. | 2001 Jun |
|
| [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs]. | 2001 Jun |
|
| Treatment of de Quervain's disease:role of conservative management. | 2001 Jun |
|
| Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro. | 2001 Jun |
|
| Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. | 2001 Jun 15 |
|
| [Nitric oxide and gastroduodenal damage caused by NSAIDs. Recent findings and clinical implications]. | 2001 Mar |
|
| Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives. | 2001 Mar |
|
| Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy. | 2001 Mar |
|
| Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs. | 2001 Mar |
|
| Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-beta-CD to HP-beta-CD. | 2001 May |
|
| Synthesis, in vitro skin permeation studies, and PLS-analysis of new naproxen derivatives. | 2001 May |
|
| [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%]. | 2001 May |
|
| Nimesulide reduces interleukin-1beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts. | 2001 May |
|
| Severe reversible renal failure due to naproxen-associated acute interstitial nephritis. | 2001 May |
|
| Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. | 2001 May |
|
| The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta-cyclodextrin. | 2001 May |
|
| Stereoselective synthesis of (S)-(+)-Naproxen catalyzed by carboxyl esterase in a multicompartment electrolyzer. | 2001 May 28 |
|
| Upper gastrointestinal toxicity of rofecoxib and naproxen. | 2001 May 3 |
|
| Upper gastrointestinal toxicity of rofecoxib and naproxen. | 2001 May 3 |
|
| Isotachophoretic determination of naproxen in the presence of its metabolite in human serum. | 2001 May 4 |
|
| Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001 May-Jun |
Patents
Sample Use Guides
Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis:
1 tablet of NAPROSYN® (250 mg or 375 mg or 500 mg) twice daily.
Acute Gout:
The recommended starting dose is 750 mg of NAPROSYN® followed by 250 mg every 8
hours until the attack has subsided.
Route of Administration:
Oral
There are data on the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen (Flu-AM1 and Nap-AM1, respectively) with respect to their properties towards fatty acid amide hydrolase (FAAH). Flu-AM1 and Nap-AM1 inhibited FAAH-catalysed hydrolysis of [(3)H]anandamide by rat brain homogenates with IC50 values of 0.44 and 0.74 uM. The corresponding values for flurbiprofen and naproxen were 29 and >100 uM, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:04:18 UTC 2021
by
admin
on
Fri Jun 25 21:04:18 UTC 2021
|
| Record UNII |
57Y76R9ATQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175722
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
CFR |
21 CFR 522.1468
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-ATC |
G02CC02
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-VATC |
QM01AE56
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-VATC |
QM02AA12
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-VATC |
QG02CC02
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
LIVERTOX |
668
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-VATC |
QM01AE52
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-ATC |
M01AE52
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-ATC |
M02AA12
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
CFR |
21 CFR 520.1468
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-VATC |
QM01AE02
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-ATC |
M01AE56
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
WHO-ATC |
M01AE02
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
||
|
NDF-RT |
N0000000160
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Naproxen
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
DB00788
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
2979
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
156391
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
C680
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
3369
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
7258
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | RxNorm | ||
|
5230
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
D009288
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
CHEMBL154
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
1883
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
1457301
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | USP-RS | ||
|
M7769
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | Merck Index | ||
|
57Y76R9ATQ
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
22204-53-1
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
SUB09159MIG
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
22204-53-1
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
NAPROXEN
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY | |||
|
244-838-7
Created by
admin on Fri Jun 25 21:04:18 UTC 2021 , Edited by admin on Fri Jun 25 21:04:18 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes
|
||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| EXCRETION | PHARMACOKINETIC |
|
|
|||
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
| MAXIMUM TOLERATED DOSE | TOXICITY |
|
||||
| Tmax | PHARMACOKINETIC |
|
FOOD EFFECT PHARMACOKINETIC |
|
||
| Tmax | PHARMACOKINETIC |
|
|
|||
| Tmax | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||